Optimization Of Simultaneous Estimation Of Candesartan And Nifedipine In Combination Therapy For Hypertension Management: A Green HPLC Approach Using Design Of Experiment Methodology
Main Article Content
Abstract
ackground: Hypertension is a prevalent health condition with severe implications for cardiovascular health. Combination therapy involving Candesartan and Nifedipine has emerged as a promising approach for managing hypertension due to the synergistic effects of these medications.
Methods: This study aimed to develop a Design of Experiment (DoE) based Green High-Performance Liquid Chromatography (HPLC) method for the simultaneous estimation of Candesartan and Nifedipine in a combined dosage form. Reversed-phase HPLC was utilized with UV-Vis spectrophotometry for detection. DoE principles were applied to optimize chromatographic conditions, including pH, ethanol percentage in the mobile phase, and flow rate.
Results: Optimal chromatographic separation was achieved using a composite mobile phase comprising ethanol and potassium dihydrogen phosphate buffer (45:55, v/v) at pH 3.7, with a flow rate of 1 mL/min. Statistical analysis confirmed the significance of these parameters in achieving efficient separation. The developed method exhibited high precision, accuracy, and reliability across various validation parameters, including specificity, linearity, repeatability, and robustness.
Conclusion: The proposed DoE-based Green HPLC method offers a sustainable and efficient approach for the simultaneous estimation of Candesartan and Nifedipine in hypertension management. By integrating green chemistry principles with systematic method development, this method provides a reliable analytical tool for routine quality control purposes in pharmaceutical formulations containing these medication
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension. 2003;41(6):1069-1116.
Wright JM, Pickering TG. Prognostic significance of asymptomatic hypertension. Arch Intern Med. 2003;163(18):2152-2160.
Agabwu MA, Adebayo GI, Onakpoya RT. The efficacy and safety of combination therapy for hypertension: a systematic review and meta-analysis. Int J Cardiol. 2017;242:130-138.
Bakris GL, Weir MR, Colucci WG, Claggett B, Needs M, Brown NJ, et al. ACC/AHA/ASH/TOS guideline for the management of high blood pressure in the adult patient: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, American Association of State and Territorial Health Officials, National Heart, Lung, and Blood Institute, Society of Hypertension, and American Society of Nephrology. Hypertension. 2014;63(e1):e1-e177.
Dunning AM, Ferrario CM. Calcium channel blockers in hypertension. Circulation. 2010;122(25):2465-2475.
McDonough FE, Ferdinand KC. Angiotensin-II receptor blockers for hypertension. Cochrane Database of Systematic Reviews. 2010;(12).
Kjeldsen SE, Cha G, Villa G, Mancia G, the DISTINCT Investigators. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. PLoS One. 2014;9(2):e88220.
Kumar V, Prasad VV, Rambabu N. A validated RP-HPLC method for the simultaneous determination of candesartan cilexetil and hydrochlorothiazide in their combined dosage form. Asian J Pharm Clin Res. 2012;5(1):71-75.
Rajani U, Reddy BS, Rambabu N. A validated RP-HPLC method for the simultaneous determination of amlodipine and olmesartan medoxomil in human plasma. J Chromatogr Sci. 2009;47(7):603-607.
Gaikwad SR, Wadodkar SB, Sawant SD. Development and validation of a stability-indicating RP-HPLC method for simultaneous determination of candesartan cilexetil and hydrochlorothiazide in pharmaceutical dosage form. J Sep Sci. 2014;37(19-20):2746-2753.
Mousavi SM, Moghadam MRT. Green analytical chemistry: an overview of its goals and benefits. Quím Nova. 2010;33(2):483-489.
Pawar SS, Khobragade MM. A validated green HPLC method for the simultaneous determination of ramipril and hydrochlorothiazide in their combined dosage form. Arab J Chem. 2016;9(1):120-127.
Aires BC, Pereira HM, Rosa JM. Greener analytical methodologies for the determination of pharmaceuticals in environmental samples: a review. Talanta. 2012;97:125-133.
Zhang Y, Liu Y, Zhou Y, Sun Y, Liu Z. Recent advances in design-of-experiment-assisted method development for pharmaceutical analysis. TrAC Trends in Analytical Chemistry. 2023;140:116332.
Li H, Zhu Y, Zhang H, Yao L, Li S. Optimization of a Stability-Indicating HPLC Method for the Determination of Five Antidepressants in Pharmaceutical Formulations Using a Design of Experiment Approach. Chromatographia. 2022;95(1-2):189-202.
Heine T, Herain M. A Review on Green Solvents for Analytical Chemistry. ChemSusChem. 2014;7(18):4618-4630.
Xu H, Sun Y, Liu Z. Design of experiments (DoE) for method development and optimization in analytical chemistry. TrAC Trends in Analytical Chemistry. 2018;109:142-152.
Poojary MM, Jain S. DoE (design of experiment) approach for development and optimization of chromatographic separations in pharmaceutical analysis. J Pharm Anal. 2014;4(4):227-234.
Zhao YZ, Wang JN, Zhang YQ. Recent developments in hyphenated chromatographic techniques and their applications in pharmaceutical analysis. J Pharm Biomed Anal. 2012;69:1-17.